{"url_path":"/sec/imnn/8-k/2026-08-11/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-037170-index.html","accession_number":"0001493152-26-037170","cik":"0000749647","ticker":"IMNN","issuer_name":"Imunon, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/749647/0001493152-26-037170-index.html","primary_entity_key":"0000749647","primary_entity_name":"Imunon, Inc."},"word_count":345,"has_tables":true,"body_markdown":"** **\n\n \n\n \n\n** **\n\n**Item\n5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n \n\nThe\nCompensation Committee and the Board of Directors of Imunon, Inc. (the “Company”), as applicable, approved compensatory programs\nfor certain executive officers, pursuant to which such executive officers may elect to receive a percentage of their base salary in the\nform of shares of common stock and will receive additional shares of common stock in connection with such election.\n\n \n\nName\nand Title\n \nPercentage\nof Base Salary that May be Paid in Shares\n \nAdditional\nShares Issuable\n\nStacy\nLindborg, President and Chief Executive Officer\n \nUp\nto 50%\n \n12%\nof the aggregate dollar amount of the net stock payment, as amended to 35% for shares issuable on August 14 and 17.5% for the shares\nissuable on each pay date beginning on August 28, 2026 and ending on September 25, 2026\n\nMichael\nTardugno, Executive Chairman\n \nUp\nto 100%\n \n20%\nof the aggregate dollar amount of the net stock payment on July 31, 40% for shares issuable on August 14 and 20% for the shares issuable\non each pay date beginning on August 28, 2026 and ending on September 25, 2026\n\nDouglas\nFaller, Chief Medical Officer\n \nUp\nto 40%\n \n12%\nof the aggregate dollar amount of the net stock payment, as amended to 15% for shares issuable on each pay date beginning on July\n31, 2026 and ending on September 25, 2026\n\n \n\nThe\nshares issuable to Dr. Lindborg and Mr. Tardugno were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities\nAct of 1933, as amended, as transactions by the Company not involving a public offering. The shares issuable to Dr. Faller will be issued\npursuant to the Imunon, Inc. 2018 Stock Incentive Plan, as amended and restated.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**IMUNON\nINC.**\n\n \n \n \n\nDated:\nAugust 11, 2026\nBy:\n*/s/\nSusan Eylward*\n\n \n \nSusan\nEylward\n\n \n \nGeneral\nCounsel and Corporate Secretary"}